Apogee Therapeutics (APGE) Receivables - Other (2023 - 2026)

Apogee Therapeutics (APGE) has 4 years of Receivables - Other data on file, last reported at $7.3 million in Q1 2026.

• Receivables - Other for Q1 2026 came in at $7.3 million, up 45.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.3 million (up 45.3% YoY), and the FY2025 annual result was $6.0 million, up 26.91% from the prior year.
• Receivables - Other climbed to $7.3 million in Q1 2026 per APGE's latest filing, from $6.0 million in the prior quarter.
• Over five years, Receivables - Other peaked at $7.3 million in Q1 2026 and troughed at $1.2 million in Q4 2023.
• A 4-year average of $4.7 million and a median of $4.7 million in 2024 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2024 and 2025: Receivables - Other soared 286.9% in 2024, then slipped 6.16% in 2025.
• A 4-year view of Receivables - Other shows it stood at $1.2 million in 2023, then soared by 286.9% to $4.7 million in 2024, then increased by 26.91% to $6.0 million in 2025, then grew by 22.14% to $7.3 million in 2026.
• Business Quant data shows APGE's Receivables - Other at $7.3 million in Q1 2026, $6.0 million in Q4 2025, and $4.5 million in Q3 2025.